Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and Degarelix with RT for IR-PCa (SChLAP/IDC)
NCT04176081Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by University Health Network. Primary endpoint: Recurrence Free Survival at 5 years. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04176081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176081.